Roxadustat

Identification

Generic Name
Roxadustat
DrugBank Accession Number
DB04847
Background

FibroGen completed the phase I single-dose, dose escalation studies as of July 2007. Multiple dose, dose escalation and phase II US studies are listed as ongoing.

Type
Small Molecule
Groups
Approved, Investigational
Structure
Thumb
Weight
Average: 352.346
Monoisotopic: 352.105921623
Chemical Formula
C19H16N2O5
Synonyms
  • Roxadustat
  • Roxadustatum
External IDs
  • ASP 1517
  • ASP-1517
  • ASP1517
  • FG 4592
  • FG-4592
  • FG4592

Pharmacology

Indication

In clinical development for the treatment of anemia of chronic inflammatory disease.

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

FG-4592 represents one of several next generation PHI that has been optimized for multiple pharmacokinetic and pharmacodynamic parameters related to erythropoiesis, including selective inhibition of HIF prolyl and asparaginyl hydroxylases, potency, iron utilization, and ADME. FG-4592 represents one of several next generation HIF-PH inhibitors designed to selectively induce the expression of genes that mediate erythropoiesis for the treatment of anemia.

Mechanism of action

FG-4592 is an orally active second generation HIF-PH inhibitor. Preclinical studies show that FG-4592 increases production of endogenous erythropoietin (EPO), increases iron mobilization and utilization, and overcomes the suppressive effects of inflammation on red blood cell production.

TargetActionsOrganism
UEgl nine homolog 1Not AvailableHumans
UEgl nine homolog 2Not AvailableHumans
UEgl nine homolog 3Not AvailableHumans
Absorption

Orally active

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
EvrenzoTablet, film coated150 mgOralAstellas Pharma Europe Bv2021-10-06Not applicableEU flag
EvrenzoTablet, film coated100 mgOralAstellas Pharma Europe Bv2021-10-06Not applicableEU flag
EvrenzoTablet, film coated20 mgOralAstellas Pharma Europe Bv2021-10-06Not applicableEU flag
EvrenzoTablet, film coated70 mgOralAstellas Pharma Europe Bv2021-10-06Not applicableEU flag
EvrenzoTablet, film coated50 mgOralAstellas Pharma Europe Bv2021-10-06Not applicableEU flag

Categories

ATC Codes
B03XA05 — Roxadustat
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as n-acyl-alpha amino acids. These are compounds containing an alpha amino acid which bears an acyl group at its terminal nitrogen atom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
N-acyl-alpha amino acids
Alternative Parents
Diarylethers / Isoquinolines and derivatives / Pyridinecarboxylic acids and derivatives / 2-heteroaryl carboxamides / Phenol ethers / Phenoxy compounds / Methylpyridines / Hydroxypyridines / Heteroaromatic compounds / Vinylogous acids
show 8 more
Substituents
2-heteroaryl carboxamide / Aromatic heteropolycyclic compound / Azacycle / Benzenoid / Carbonyl group / Carboxamide group / Carboxylic acid / Diaryl ether / Ether / Heteroaromatic compound
show 19 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
X3O30D9YMX
CAS number
808118-40-3
InChI Key
YOZBGTLTNGAVFU-UHFFFAOYSA-N
InChI
InChI=1S/C19H16N2O5/c1-11-15-9-13(26-12-5-3-2-4-6-12)7-8-14(15)18(24)17(21-11)19(25)20-10-16(22)23/h2-9,24H,10H2,1H3,(H,20,25)(H,22,23)
IUPAC Name
2-[(4-hydroxy-1-methyl-7-phenoxyisoquinolin-3-yl)formamido]acetic acid
SMILES
CC1=NC(C(=O)NCC(O)=O)=C(O)C2=C1C=C(OC1=CC=CC=C1)C=C2

References

General References
Not Available
KEGG Drug
D10593
PubChem Compound
11256664
PubChem Substance
347827699
ChemSpider
9431690
BindingDB
50431015
ChEBI
132774
ChEMBL
CHEMBL2338329
ZINC
ZINC000071257465
PDBe Ligand
8HO
Wikipedia
Roxadustat
PDB Entries
6kkb / 6kke / 6knu / 6knv / 6knw

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Active Not RecruitingTreatmentAnemia of Chronic Kidney Disease / Coronavirus Disease 2019 (COVID‑19)1
4RecruitingTreatmentCKD Anemia in Dialysis Patients1
4RecruitingTreatmentRenal Anemia1
3Active Not RecruitingTreatmentAnemia Associated With End Stage Renal Disease (ESRD)2
3CompletedTreatmentAnemia4
3CompletedTreatmentAnemia in Chronic Kidney Disease in Non-dialysis Patients2
3CompletedTreatmentAnemia in Incident Dialysis Patients1
3CompletedTreatmentAnemia / End Stage Renal Disease (ESRD)1
3CompletedTreatmentChronic Kidney Disease (CKD)2
3CompletedTreatmentCKD Anemia1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Tablet, film coatedOral100 mg
Tablet, film coatedOral150 mg
Tablet, film coatedOral20 mg
Tablet, film coatedOral50 mg
Tablet, film coatedOral70 mg
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0115 mg/mLALOGPS
logP3.13ALOGPS
logP1.85ChemAxon
logS-4.5ALOGPS
pKa (Strongest Acidic)2.75ChemAxon
pKa (Strongest Basic)3.84ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area108.75 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity92.85 m3·mol-1ChemAxon
Polarizability35.7 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Targets

Drugtargets2
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Peptidyl-proline dioxygenase activity
Specific Function
Cellular oxygen sensor that catalyzes, under normoxic conditions, the post-translational formation of 4-hydroxyproline in hypoxia-inducible factor (HIF) alpha proteins. Hydroxylates a specific prol...
Gene Name
EGLN1
Uniprot ID
Q9GZT9
Uniprot Name
Egl nine homolog 1
Molecular Weight
46020.585 Da
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Peptidyl-proline 4-dioxygenase activity
Specific Function
Cellular oxygen sensor that catalyzes, under normoxic conditions, the post-translational formation of 4-hydroxyproline in hypoxia-inducible factor (HIF) alpha proteins. Hydroxylates a specific prol...
Gene Name
EGLN2
Uniprot ID
Q96KS0
Uniprot Name
Egl nine homolog 2
Molecular Weight
43650.03 Da
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Peptidyl-proline 4-dioxygenase activity
Specific Function
Cellular oxygen sensor that catalyzes, under normoxic conditions, the post-translational formation of 4-hydroxyproline in hypoxia-inducible factor (HIF) alpha proteins. Hydroxylates a specific prol...
Gene Name
EGLN3
Uniprot ID
Q9H6Z9
Uniprot Name
Egl nine homolog 3
Molecular Weight
27261.06 Da

Drug created on October 18, 2007 19:34 / Updated on October 13, 2021 09:30